Advisor Group’s Adamas Pharmaceuticals ADMS Stock Holding History

Advisor Group’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$29K	Sell	7,525 -675	-8%	-$3.23K	﹤0.01%	3758
2019 Q3	$42K	Sell	8,200 -3,000	-27%	-$18.5K	﹤0.01%	3522
2019 Q2	$69K	Buy	11,200 +3,900	+53%	+$22.4K	﹤0.01%	3141
2019 Q1	$52K	Buy	7,300 +1,000	+16%	+$8.99K	﹤0.01%	3366
2018 Q4	$54K	Buy	6,300 +4,510	+252%	+$58.7K	﹤0.01%	3131
2018 Q3	$36K	Buy	1,790 +1,590	+795%	+$37.3K	﹤0.01%	3526
2018 Q2	$5K	Hold	200	–	–	﹤0.01%	4416
2018 Q1	$5K	Sell	200 -200	-50%	-$6.31K	﹤0.01%	4449
2017 Q4	$14K	Buy	+400	New	+$11.2K	﹤0.01%	3915

Other funds holding ADMS

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Advisor Group's ADMS Position: Q4 2019 in Review

Advisor Group reduced its Adamas Pharmaceuticals (ADMS) stake by 8.2% in Q4 2019, selling an estimated $3.23K and leaving 7,525 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #3758.

Advisor Group first reported a position in ADMS in Q4 2017 and has held it in 9 quarters since. The position peaked at $69K in Q2 2019. 79 funds tracked by Wall St. Rank hold ADMS as of Q4 2019.

Advisor Group held 7,525 shares of Adamas Pharmaceuticals worth $29K as of Q4 2019.
Advisor Group sold 675 Adamas Pharmaceuticals shares in Q4 2019, an estimated $3.23K.
Adamas Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3758 holding.
Advisor Group first reported a position in Adamas Pharmaceuticals in Q4 2017 and has held it in 9 quarters since.
Advisor Group's Adamas Pharmaceuticals position peaked at $69K in Q2 2019.
79 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.